Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis

Table 5

Case by case analysis of nine AFP ≥ 20 ng/ml GCLM received triplet regimen as first-line chemotherapy.

(a)

Age/sex	Primary lesion site	Histological type	Serum AFP level (ng/ml)	Lauren classification	HER2 status	PVTT	Peritoneal metastasis
34/M	Body	GHA	455	Intestinal	Negative	No	No
59/M	Antrum	GHA	208,072	NK	NK	No	No
43/M	Body	Poorly differentiated adenocarcinoma	7307	NK	NK	Yes	No
58/M	Antrum	Poorly differentiated adenocarcinoma	113	Mixed	Negative	No	No
39/F	Body	Poorly differentiated adenocarcinoma	3042	Diffuse	Negative	No	Yes
56/F	Antrum	Middle-differentiated adenocarcinoma	22	Intestinal	Positive	No	No
75/F	Antrum	Middle-differentiated adenocarcinoma	131	NK	NK	No	No
59/M	Body	Middle-differentiated adenocarcinoma	2108	NK	NK	No	No
42/M	GEJ	GHA	868	Mixed	Negative	Yes	No

(b)

Regimen	Cycles	Evaluation	PFS (m)	≥grade 3 toxicity	Other treatments	OS (m)	Follow-up status
PCF	4	PR	9.5	BWL	FOLFIRINOX; olaparib; apatinib; PD-1 antibody; TACE	22.8	Alive
PCF	6	PR	4.2	Vomiting	No	7.1	Dead
POS	5	SD	6.0	No	No	11.0	Alive
POS	5	PR	6.2	Hematological; sensory neuropathy	Radiotherapy	8.0	Alive
DCF	1	PD	0.8	No	No	1.7	Dead
ECF	6	PR	6.1	No	Herceptin; TACE	37.6	Dead
DCF	4	PR	3.4	Hematological; vomiting; mucosal reaction	No	10.9	Dead
PCF	3	PR	2.6	Cardiac toxicity	Gastrectomy	10.9	Dead
POS	5	SD	5.83	Hematological	Gastrectomy; liver resection; apatinib; PD-1 antibody	13.6	Alive

F = female; M = male; NK = not known; BWL = body weight loss; PVTT = portal vein tumor thrombus; PCF = paclitaxel + cisplatin+ 5-fluorouracil; POS = paclitaxel + oxaplatin + S-1; DCF = docetaxel + cisplatin+ 5-fluorouracil; ECF = epirubicin + cisplatin+ 5-fluorouracil.